These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25293578)

  • 21. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value.
    Flamm RK; Stone GG; Sader HS; Jones RN; Nichols WW
    J Chemother; 2014 Dec; 26(6):333-8. PubMed ID: 24125508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens.
    Stone GG; Bradford PA; Newell P; Wardman A
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftazidime/avibactam susceptibility by three different susceptibility testing methods in carbapenemase-producing Gram-negative bacteria from Australia.
    Sherry NL; Baines SL; Howden BP
    Int J Antimicrob Agents; 2018 Jul; 52(1):82-85. PubMed ID: 29499316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).
    Sader HS; Castanheira M; Mendes RE; Flamm RK
    J Antimicrob Chemother; 2018 Nov; 73(11):3053-3059. PubMed ID: 30060117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
    Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA
    ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Mawal Y; Critchley IA; Riccobene TA; Talley AK
    Expert Rev Clin Pharmacol; 2015; 8(6):691-707. PubMed ID: 26420166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.
    Levasseur P; Girard AM; Miossec C; Pace J; Coleman K
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1931-4. PubMed ID: 25583732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.
    Wenzler E; Deraedt MF; Harrington AT; Danizger LH
    Diagn Microbiol Infect Dis; 2017 Aug; 88(4):352-354. PubMed ID: 28602518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications.
    Sherry N; Howden B
    Expert Rev Anti Infect Ther; 2018 Apr; 16(4):289-306. PubMed ID: 29543500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).
    Sader HS; Castanheira M; Jones RN; Flamm RK
    Diagn Microbiol Infect Dis; 2017 Mar; 87(3):261-265. PubMed ID: 28069328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
    Castanheira M; Mills JC; Costello SE; Jones RN; Sader HS
    Antimicrob Agents Chemother; 2015; 59(6):3509-17. PubMed ID: 25845862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.
    Winkler ML; Papp-Wallace KM; Bonomo RA
    J Antimicrob Chemother; 2015 Aug; 70(8):2279-86. PubMed ID: 25957381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).
    Sader HS; Castanheira M; Farrell DJ; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2015 Dec; 83(4):389-94. PubMed ID: 26162518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftazidime/Avibactam: Who Says You Can't Teach an Old Drug New Tricks?
    Barber KE; Ortwine JK; Akins RL
    J Pharm Pharm Sci; 2016; 19(4):448-464. PubMed ID: 28057163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
    Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
    Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
    Humphries RM; Yang S; Hemarajata P; Ward KW; Hindler JA; Miller SA; Gregson A
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6605-7. PubMed ID: 26195508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.
    Berkhout J; Melchers MJ; van Mil AC; Nichols WW; Mouton JW
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1138-44. PubMed ID: 25487794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.
    Lahiri SD; Walkup GK; Whiteaker JD; Palmer T; McCormack K; Tanudra MA; Nash TJ; Thresher J; Johnstone MR; Hajec L; Livchak S; McLaughlin RE; Alm RA
    J Antimicrob Chemother; 2015; 70(6):1650-8. PubMed ID: 25645206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.